CELLDEX THERAPEUTICS INC

Celldex Therapeutics: Exploring immune‑based therapies for cancer, autoimmune, and cardiovascular diseases, backed by robust R&D and a $2.8 billion market cap.

Celldex Therapeutics closes $345 M public offering, raising capital to accelerate its immunology‑focused pipeline while adding 11.9 M shares and 1.55 M option shares.

Celldex Therapeutics Inc. has reported promising clinical trial results for its drug barzolvolimab, showing significant efficacy in treating angioedema associated with chronic spontaneous urticaria.

Celldex Therapeutics Inc. is poised for significant growth after presenting promising results from its Phase 2 study of barzolvolimab, a potential treatment for chronic spontaneous urticaria.

Celldex Therapeutics Inc. is a leading biopharmaceutical company making significant strides in immunological applications, with a strong pipeline of potential therapies and a commitment to addressing unmet medical needs.

Celldex Therapeutics Inc. is a pioneering biotech company harnessing immunology to develop groundbreaking therapies for a range of diseases, with a promising pipeline and a commitment to innovation in the face of industry challenges.